Citi lowered the firm’s price target on Biomea Fusion (BMEA) to $6 from $7 and keeps a Buy rating on the shares following the Q3 report. The firm cites the company’s higher spending and dilution from the recent public offering for the target drop.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA: